$260,000.00 in Sales Expected for Autolus Therapeutics plc (NASDAQ:AUTL) This Quarter

Equities research analysts predict that Autolus Therapeutics plc (NASDAQ:AUTLGet Rating) will post $260,000.00 in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Autolus Therapeutics’ earnings, with the lowest sales estimate coming in at $220,000.00 and the highest estimate coming in at $300,000.00. Autolus Therapeutics reported sales of $1.65 million in the same quarter last year, which indicates a negative year over year growth rate of 84.2%. The company is scheduled to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Autolus Therapeutics will report full-year sales of $940,000.00 for the current year, with estimates ranging from $870,000.00 to $1.00 million. For the next financial year, analysts forecast that the business will report sales of $4.12 million, with estimates ranging from $1.00 million to $8.70 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Autolus Therapeutics.

Autolus Therapeutics (NASDAQ:AUTLGet Rating) last announced its quarterly earnings data on Thursday, May 5th. The company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.10. Autolus Therapeutics had a negative net margin of 6,098.54% and a negative return on equity of 49.80%. During the same quarter in the prior year, the company posted ($0.53) earnings per share.

AUTL has been the topic of a number of recent analyst reports. William Blair reaffirmed an “outperform” rating on shares of Autolus Therapeutics in a research note on Thursday, March 10th. Zacks Investment Research cut shares of Autolus Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, February 21st. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Autolus Therapeutics presently has an average rating of “Buy” and an average price target of $11.75.

NASDAQ:AUTL opened at $2.84 on Friday. Autolus Therapeutics has a fifty-two week low of $2.83 and a fifty-two week high of $8.23. The stock has a market cap of $258.18 million, a PE ratio of -1.43 and a beta of 1.60. The firm’s fifty day simple moving average is $3.89 and its 200-day simple moving average is $4.78.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. LGT Capital Partners LTD. acquired a new stake in Autolus Therapeutics in the 1st quarter valued at about $2,085,000. BlackRock Inc. grew its stake in Autolus Therapeutics by 214.5% in the 4th quarter. BlackRock Inc. now owns 471,733 shares of the company’s stock valued at $2,448,000 after acquiring an additional 321,761 shares during the last quarter. Woodline Partners LP purchased a new position in Autolus Therapeutics in the 4th quarter valued at about $4,868,000. Goldman Sachs Group Inc. lifted its holdings in Autolus Therapeutics by 172.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 153,421 shares of the company’s stock valued at $796,000 after purchasing an additional 97,030 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in Autolus Therapeutics in the 4th quarter valued at about $88,000. 61.45% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile (Get Rating)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma.

Further Reading

Get a free copy of the Zacks research report on Autolus Therapeutics (AUTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.